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Autophagy is induced in the 
skeletal muscle of cachectic  
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Cesarina Ramaccini1, Paola Costelli2,3 & Maurizio Muscaritoli1
Basal rates of autophagy can be markedly accelerated by environmental stresses. Recently, autophagy 
has been involved in cancer-induced muscle wasting. Aim of this study has been to evaluate if 
autophagy is induced in the skeletal muscle of cancer patients. The expression (mRNA and protein) 
of autophagic markers has been evaluated in intraoperative muscle biopsies. Beclin-1 protein levels 
were increased in cachectic cancer patients, suggesting autophagy induction. LC3B-I protein levels 
were not significantly modified. LC3B-II protein levels were significantly increased in cachectic 
cancer patients suggesting either increased autophagosome formation or reduced autophagosome 
turnover. Conversely, p62 protein levels were increased in cachectic and non-cachectic cancer patients, 
suggesting impaired autophagosome clearance. As for mitophagy, both Bnip3 and Nix/Bnip3L show 
a trend to increase in cachectic patients. In the same patients, Parkin levels significantly increased, 
while PINK1 was unchanged. At gene level, Beclin-1, p-62, BNIP3, NIX/BNIP3L and TFEB mRNAs 
were not significantly modulated, while LC3B and PINK1 mRNA levels were increased and decreased, 
respectively, in cachectic cancer patients. Autophagy is induced in the skeletal muscle of cachectic 
cancer patients, although autophagosome clearance appears to be impaired. Further studies should 
evaluate whether modulation of autophagy could represent a relevant therapeutic strategy in cancer 
cachexia.
Cancer patients frequently experience cachexia, a complex multifactorial syndrome associated to serious clinical 
consequences1. Muscle wasting is a major feature in cancer cachexia and negatively affects patients’ outcome, 
quality of life and response to anti-neoplastic treatments2,3. The mechanisms underlying muscle wasting in can-
cer cachexia are still not completely understood, although several studies suggest that hyperactivation of cellular 
degradative pathways, such as the ubiquitin proteasome system, plays a major role2. Recently also the autophagic 
degradation has been suggested to be involved in the pathogenesis of muscle wasting under different catabolic 
conditions including cancer4,5. Macroautophagy (hereafter referred to as autophagy) is a highly conserved home-
ostatic mechanism involved in the lysosomal-dependent degradation of cellular constituents including bulk 
cytoplasm, long-lived or misfolded proteins, damaged organelles, toxic protein aggregates and intracellular path-
ogens. Autophagy constantly works at basal levels in all eukaryotic cells to ensure a quality-control of cytoplasmic 
components and prevent accumulation of degenerated protein and organelles6,7. However, under marked nutrient 
restriction and other stress conditions, autophagy is rapidly up-regulated in order to replace old or damaged 
cellular constituents, recycle biomolecules for the synthesis of new components and mobilize cellular energy 
stores8,9.
In the initial step of autophagy, a small portion of cytoplasm, including organelles or soluble materials, is 
sequestered by an isolation membrane (phagophore) to form an autophagosome. The autophagosome then fuses 
with the lysosome to become an autolysosome and degrade the cargo contained within it6,7.
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Autophagy was initially considered a non-selective degradation pathway of bulk cytoplasm, but increasing 
evidences have shown that it can be involved also in the selective removal of protein aggregates or specific orga-
nelles such as mitochondria via mithophagy, ribosomes via ribophagy, peroxisomes via pexophagy and many oth-
ers4,9. The selectivity of autophagic degradation is conferred by specific signals such as p62, Bnip3, Nbr1, which 
have both a cargo-binding domain (that recognizes and attaches organelles) and a LC3-interacting region (LIR), 
that recruits and binds essential autophagosome membrane proteins10. Adaptor proteins are able to recognize 
their target by specific flag molecules or post-translational modifications, such as ubiquitylation, phosphorylation 
and acetylation, presented on the surface of the cargo11,12.
Recent findings suggest that autophagy plays a central role in the regulation of muscle homeostasis both under 
constitutive conditions and in response to various stimuli such as cellular stress, fasting or exercise4. Indeed, skel-
etal muscle is a crucial metabolic center, and an efficient autophagic flux is fundamental to guarantee a rapid and 
proper turnover of cell components12. The pivotal role played by autophagy in the regulation of skeletal muscle 
mass is underscored by the phenotypes of mice with muscle specific ablation of genes encoding autophagy-related 
proteins13. Indeed, muscle-specific deletion of a gene crucial for autophagy such as Atg7 resulted in profound 
muscle atrophy and age-dependent decrease in force14.
Alterations in autophagic degradation with accumulation of unfolded and aggregate-prone proteins and dys-
functional organelles is a typical feature of several myopathies4,13,15,16. Disorders in which autophagic vacuoles are 
seen in the skeletal muscle are generally referred to as authophagic vacuolar myopathies which include Pompe 
disease and Danon disease17. Recently, however, defective autophagy has been demonstrated to contribute also to 
the pathogenesis of different forms of muscular dystrophies which could display either accumulation of altered 
organelles inside myofibers (impaired autophagy), or excessive degradation of myofiber components (excess 
autophagy)4.
A modulation of autophagy has been reported in the skeletal muscle also during several conditions such as 
fasting18,19, exercise20, ageing21,22, sepsis23, denervation24, disuse25, critical illness26,27, cirrhosis28, COPD29,30 and 
cancer21. In this regard, autophagy has been shown to contribute to muscle atrophy in three different experimen-
tal models of cancer cachexia21 and a modulation of representative markers of this degradative pathway has been 
documented in the skeletal muscle of esophageal31, lung32, upper gastrointestinal and pancreatic33 cancer patients. 
At present, however, the role of autophagy in the pathophysiology of human cancer-related muscle loss is not yet 
fully elucidated. This is due, at least in part, to the impossibility to dynamically assess, in the clinical setting, the 
autophagic flux with the techniques currently available34.
Aim of the present study was to provide a comprehensive panel of autophagy and mitophagy markers, at both 
the gene and protein level, in order to better clarify to what extent autophagy is involved in the pathogenesis of 
cancer-induced muscle loss.
Materials and Methods
Patients. The methods were carried out in accordance with the approved guidelines and regulations. After 
approval of the local ethical committees at M.G. Vannini Hospital in Rome (Italy) and Azienda Ospedaliera 
Universitaria Senese in Siena (Italy), and after the obtainment of written informed consent, twenty-nine con-
secutive cancer patients (17 males and 12 females) were enrolled among those undergoing abdominal surgery 
(Table 1). Age and sex matched controls patients were recruited among those undergoing abdominal surgery 
for non-neoplastic diseases (6 males and 5 females). Reasons for abdominal surgery in controls were: incisional 
hernia, cholelithiasis, benign prostatic hyperplasia, epigastric hernia and mesenteric cyst.
Exclusion criteria for both cancer patients and controls were: liver failure, diabetes, metabolic acidosis, acute 
and chronic renal failure, sepsis, AIDS, inflammatory bowel diseases, acute and chronic hepatitis, autoimmune 
disorders and chronic obstructive pulmonary disease.
Nutritional assessment and body composition evaluation. The nutritional assessment included 
anthropometric [height, actual body weight, % body weight loss (BWL) during the previous 6 months, body mass 
index (BMI), usual body weight], immunological (total lymphocyte count), and biochemical (serum albumin) 
indices. Blood samples were collected before the surgical procedure and analyzed in the hospital clinical labo-
ratory to evaluate, besides total lymphocyte count and serum albumin, the following parameters: haemoglobin, 
white cell count, serum total protein, C-reactive protein, ferritin, serum iron, creatinine, total cholesterol, HDL 
cholesterol, LDL cholesterol and triglycerides.
The presence of anorexia was evaluated using the anorexia questionnaire35, that investigates the presence 
of early satiety, taste/smell alterations, meat aversion, nausea/vomiting. Patients reporting at least one of these 
symptoms were considered as anorectic. Patients were also asked to report on the visual analogic scale (VAS) their 
self-assessment of appetite. The VAS consisted of a line of 100 mm, the extremities being anchored to “hunger” 
(0 mm) and “no hunger” (100 mm).
Body composition was assessed by bioelectrical impedance analysis (BIA) in all patients included in the study.
Finally, patients were assessed for the presence of pre-cachexia or cachexia according to the current available 
diagnostic criteria1,36. In particular, pre-cachexia was defined according to the ESPEN Special Interest Group 
(SIG) on cachexia-anorexia in chronic wasting diseases consensus definition36 by the presence of all the following 
criteria:
(a) Weight loss ≤ 5% of usual body weight in the last 6 months;
(b)  Systemic inflammatory response indicated by C-reactive protein (CRP) above the upper limit of normality for 
the method used (> 0.5 mg/dl in this study);
(c) Anorexia or anorexia-related symptoms.
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Patients were classified as cachectic when they showed BWL > 5% in the previous 6 months according the 
International Consensus definition on cancer cachexia1.
Muscle biopsy. Biopsy specimens were obtained during the initial phase of the operation from the rectus 
abdominis muscle. After skin incision and dissection through the subcutaneous fat, the anterior sheet of the 
rectus abdominis muscle was opened with scissors and a muscle biopsy specimen was obtained (approximately 
0.5 g). Small bleeding vessels were carefully controlled with ligatures and cautery after the muscle biopsy had been 
obtained; thereafter the operation continued in a routine fashion. No complications occurred from the biopsy 
procedure. Biopsy specimens were immediately frozen in liquid nitrogen and stored at − 80 °C until analysis; part 
of the specimens was used for the present study and part was kept stored for further, subsequent investigations.
Real-time PCR. Total RNA was obtained using TriReagent (Sigma Aldrich, St. Louis MO) following the 
manufacturer’s instructions. RNA concentration was determined fluorometrically using the RiboGreen reagent 
(Invitrogen, Carlsbad CA).
Total mRNA was retrotranscribed using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Transcript 
levels were determined by real-time PCR using the SsoFast EvaGreen Supermix and the MiniOpticon Thermal 
Cycler (Bio-Rad). Ten seconds of denaturation at 95 °C was followed by 30 seconds of annealing/extension at 
60 °C and repeated for 40 cycles. Every qPCR was validated by analyzing the respective melting curve. Only one 
peak was detectable, indicating the presence of just one amplicon.
Gene expression was normalized to both GAPDH and TATA-binding protein (TBP) expression and calculated 
using the 2−ΔΔCt method.
Primers sequences used (forward and reverse) are indicated in Supplementary Table S1 (see supplementary 
information).
Western blotting. Approximately 50 mg of rectus abdominis muscle was homogenized in a buffer containing 
10 mM HEPES pH 7.5, 10 mM MgCl2, 5 mM KCl, 0.1 mM EDTA pH 8.0, 0.1% TritonX-100, 1 mM dithiothreitol, 
0.1 mM PMSF, with freshly added protease and phosphatase inhibitor cocktails; centrifuged at 3000 × g for 4 min-
utes at 4 °C; and the supernatant collected (cytosolic proteins). The pellet obtained was resuspended in a buffer 
containing 20 mM HEPES pH 7.9, 25% glycerol, 500 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA pH 8.0, 0.5 mM 
dithiothreitol, 0.2 mM PMSF and freshly added protease and phosphatase inhibitor cocktails; kept on ice for 
30 minutes (vortexing samples every 10 minutes); centrifuged at 3000 × g for 4 minutes at 4 °C; and the superna-
tant collected (nuclear proteins). Protein concentration was determined by using the Bradford reagent (Bio-Rad) 
with bovine serum albumin as standard.
Equal amount of proteins (30 μ g) were heat denatured in sample loading buffer (50 mm Tris–HCl, pH 
6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol) resolved by SDS-page and transferred to 
Nitrocellulose or PVDF membrane (Bio-Rad). Protein transfer was checked by Ponceau-S staining. The filters 
were blocked with Tris-Buffered saline containing 0.05% Tween-20 and 5% non-fat dry milk and then were 
incubated overnight with the following primary antibodies: a rabbit polyclonal anti- human beclin-1 (B6186, 
Variables Cancer patients Control patients
Subjects (n) 29 11
Age (years) 68 ± 2 63 ± 4
Sex 
 Male (n) 17 7
 Female (n) 12 4
Cancer site —
 Colon-rectum (n) 14
 Pancreas (n) 5
 Stomach (n) 4
 Miscellaneous (n) 6
Cancer stage
 I-II (n) 9
 III-IV (n) 20
Height (m) 1.64 ± 0.02 1.67 ± 0.03
Weight at diagnosis (kg) 71.3 ± 2.9 76.7 ± 4.7
BMI at diagnosis (kg/m2) 26.6 ± 0.94 27.4 ± 1.5
% body weight loss over last 6 months 6.7 ± 1.5 —
Patients with anorexia (n) 11 —
Cachexia classification 
 Pre-cachexia (n) 3 —
 Cachexia (n) 12 —
 No pre-cachexia/no cachexia (n) 14 —
Table 1.  Characteristics of the study population.
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Sigma, St. Louis, MO, USA), a rabbit polyclonal anti-human LC3B (#L7543, Sigma Aldrich), a rabbit polyclonal 
anti-human p62/SQSTM1 (#P0067, Sigma Aldrich), a rabbit polyclonal anti- human Bnip3 (#38621; Abcam, 
Cambridge, UK), a rabbit polyclonal anti-human Nix/Bnip3L (#N0399, Sigma Aldrich), a mouse monoclo-
nal anti-human Parkin (#P6248, Sigma Aldrich), a goat polyclonal anti-human PINK1 (#SAB2500794, Sigma 
Aldrich) and a goat polyclonal anti-human TFEB (#2636, Abcam). A goat polyclonal anti-human GAPDH anti-
body (sc-20357, Santa Cruz Biotechnology, Santa Cruz, CA) and a rabbit polyclonal anti Lamin A antibody (sc-
20680, Santa Cruz Biotechnology, Santa Cruz, CA) were used as loading control for cytosolic and nuclear extracts, 
respectively. Peroxidase conjugated IgG were used as secondary antibodies. Immunoreactive protein bands were 
detected by enhanced chemoluminescence on a photon sensitive film. Molecular weights of protein bands were 
determined by Dual Precision molecular weight standards (Bio-Rad). Quantification of the bands was performed 
by densitometric analysis using the software TotalLab (NonLinear Dynamics, New Castle on Tyne, UK). Since the 
western blotting were performed in the presence of DTT, only Bnip3 monomeric form could be detected37. Purity 
of the obtained nuclear and cytosolic fractions were checked by probing the membrane for Lamin A (nuclear) 
and tubulin (cytosolic; #T5168, Sigma Aldrich). A representative pattern is reported in Supplementary Figure S1. 
Although fractions were not totally pure, nuclear protein enrichment was considered acceptable. Indeed, Lamin 
A/tubulin ratio was markedly and significantly higher in the nuclear than in the cytosolic fractions.
Statistics. Data are expressed as means ± standard error (SEM). Statistical analysis was performed by using 
Mann-Whitney or Kruskal Wallis test followed by post hoc test as appropriate. p < 0.05 was considered statisti-
cally significant.
Results
Clinical characteristics of the subjects studied are shown on Table 1. The mean age of cancer and control patients 
was over 60 years (cancer patients, 68 ± 2 years; control patients 63 ± 4 years, p = n.s.), with a similar propor-
tion of male and female subjects in the two groups. The mean BMI was not different between cancer and con-
trol patients and lied in the overweight zone for both groups. Despite this, cancer patients presented in the last 
six months an average percent of body weight loss of 6.7 ± 1.5 (range: 0–33%), and 38% of them complained 
anorexia-related symptoms.
When cancer patients were classified upon the concepts of the SIG-ESPEN and the International Consensus 
definition on cancer cachexia1,36, pre-cachexia was present in 3 cancer patients, cachexia in 12 cancer patients, 
while 14 cancer patients did not match either criteria and were considered non-cachectic. Since the small number 
Variables Control patients Non cachectic cancer patients Cachectic cancer patients
BMI (kg/m2) 27.4 ± 1.5 28.3 ± 1.1 24.5 ± 1.5a,b
% body weight loss over last 6 months — 0.6 ± 0.3 13.3 ± 2.00b
FFM (kg) 50.96 ± 3.00 50.79 ± 2.24 43.13 ± 2.38a,b
FFMI (kg/m2) 18.08 ± 0.71 18.56 ± 0.49 16.38 ± 0.74b
FM (kg) 25.73 ± 2.89 26.33 ± 2.57 24.89 ± 4.80
FMI (kg/m2) 9.28 ± 1.10 9.69 ± 0.91 9.24 ± 1.55
Phase angle (°) 5.63 ± 0.29 5.75 ± 0.37 5.09 ± 0.39
Table 2. Anthropometric and BIA-derived parameters in patients stratified for cachexia. ap < 0.05 vs 
control patients. bp < 0.05 vs non cachectic cancer patients. Abbreviations: BIA, bioelectrical impedance 
analysis. BMI, Body Mass Index; FFM, Fat Free Mass; FFMI, Fat Free Mass Index; FM, Fat Mass; FMI, Fat Mass 
Index.
Variables Control patients Non cachectic cancer patients Cachectic cancer patients
Serum total protein (g/dL) 6.8 ± 0.2 6.7 ± 0.3 6.3 ± 0.2
Serum albumin (g/dL) 4.2 ± 0.1 3.8 ± 0.2 3.5 ± 0.2a
C-reactive protein (mg/dL) 0.45 ± 0.17 1.92 ± 1.04 2.07 ± 0.98
Ferritin (ng/mL) 125 ± 32 198 ± 61 156 ± 31
Serum iron (μg/mL) 109 ± 16 63 ± 8 70 ± 10
Serum creatinine (mg/dL) 0.95 ± 0.06 0.96 ± 0.08 0.8 ± 0.05
Total cholesterol (mg/dL) 179 ± 21 168 ± 11 178 ± 11
HDL cholesterol (mg/dL) 51 ± 2 45 ± 6 44 ± 5
LDL cholesterol (mg/dL) 125 ± 18 92 ± 10 114 ± 12
Triglycerides (mg/dL) 100 ± 15 123 ± 15 109 ± 11
Haemoglobin (g/dL) 14.4 ± 0.4 12.4 ± 0.5a 12.1 ± 0.4a
White cell count (x103/cm3) 6.17 ± 0.3 7.7 ± 0.99 5.6 ± 0.5
Total lymphocytes count (x103/cm3) 1.9 ± 0.096 1.7 ± 0.19 1.4 ± 0.20a
Table 3.  Biochemical and hematological indices in patients stratified for cachexia. ap < 0.05 vs control 
patients.
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of patients with pre-cachexia might have affected statistical analysis, we decided hereafter to merge pre-cachectic 
with non-cachectic cancer patients into one single group (n = 17).
Body composition assessed with BIA, showed that both fat free mass (FFM) and fat free mass index (FFMI) 
were significantly reduced in cachectic versus non-cachectic cancer patients, suggesting that anthropometric 
measurements correctly identified patients’ categories (Table 2).
All cancer patients (cachectic and non-cachectic) had mild anemia, with haemoglobin levels significantly 
reduced with respect to controls (Table 3). Interestingly and not surprisingly, only cachectic cancer patients had 
significantly lower serum albumin and total lymphocytes count when compared to controls (Table 3), while 
C-reactive protein levels, were increased in both non-cachectic and cachectic cancer patients, although this dif-
ference did not reach statistical significance (Table 3). All the other biochemical parameters evaluated were not 
statistically different among the study groups (Table 3).
To estimate the activation of the autophagic-lysosomal degradative pathway, we assessed muscle expression of 
proteins commonly recognized as autophagy markers34 in rectus abdominis muscle biopsies obtained intraoper-
atively from surgical cancer and control patients.
We first evaluated the expression of Beclin-1, a protein essential for the initiation of autophagy, the levels of 
which are considered a marker of autophagy induction38,39. Beclin-1 mRNA levels were unchanged (Fig. 1A), 
while Beclin-1 protein expression was significantly increased in the skeletal muscle of cachectic cancer patients 
(Fig. 1C) suggesting autophagy activation.
We next evaluated the expression of the microtubule-associated protein 1 light chain 3B (LC3B), a 
ubiquitin-like molecule that is the mammalian homologue of the yeast Atg8 and is essential for autophagosome 
formation40. LC3B mRNA levels were significantly increased in cachectic cancer patients (Fig. 1B) suggesting 
transcriptional induction. As LC3B before targeting the autophagosome undergoes post-translational modifica-
tions that influence its activity and are used as marker of autophagosome formation34, we next evaluated protein 
expression of the LC3B isoform I (LC3BI), that resides in the cytosol and has a carboxyterminal glycine, and the 
lipidated isoform II (LC3B-II), that is tightly associated to autophagosome membrane and results by conjugation 
Figure 1. Beclin-1 and LC3B expression in rectus abdominis muscle of cancer and control patients.  
(A) Beclin-1 and (B) LC3B mRNA levels were evaluated by real-time PCR (control, n = 11; non cachectic cancer 
patients, n = 17; cachectic cancer patients, n = 12); (C) Beclin-1 and (D) LC3BI and LC3BII protein levels were 
evaluated by western blotting (control, n = 9; non cachectic cancer patients, n = 16; cachectic cancer patients, 
n = 10): representative western blots for Beclin-1, LC3BI, LC3BII and GAPDH (loading control) are shown on 
the lower panel and densitometric quantifications of Beclin-1, LC3B-I and LC3B-II protein levels normalized to 
GAPDH are shown on the upper panel. Representative pattern for Beclin-1, group ‘Cancer no cachexia’ consists 
of two non adjacent lanes on the same blot. The whole blot is reported in Supplementary Figure S2. Data 
(mean ± SEM) are expressed as percentage of controls. Significance of the differences: * p < 0.05 vs controls; 
#p < 0.05 vs cancer no cachexia.
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of LC3B-I with phosphatidylethanolamine41. We found that LC3B-I protein levels were not significantly mod-
ified in cancer patients, while LC3B-II protein levels were significantly increased in cachectic cancer patients 
(Fig. 1D) suggesting either autophagosome formation or reduced autophagosome turnover. Unfortunately, it was 
not possible to discern this point by means of flux experiments using autophagy inhibitors such as colchicine or 
bafilomycin A142,43, being this a study on human muscle biopsies.
Thus, we proceeded with the evaluation of p62/SQSTM1 (hereafter referred to as p62), an adaptor mole-
cule involved in selectively targeting protein aggregates to autophagosomes by simultaneously binding LC3B 
and ubiquitinated proteins44. Since p62 is constantly removed by autophagy, it is considered a good marker of 
autophagic vescicle turnover34. p62 mRNA levels were not significantly modified (Fig. 2A), while p62 protein 
levels were increased in all cancer patients (Fig. 2B) suggesting impaired autophagosome clearance, possibly due 
to exhaustion of the lysosomal degradative capacity.
Since autophagy is important also for the removal of dysfunctional organelles such as mitochondria45, we 
next examined the expression of Bnip3, Nix/Bnip3L, Parkin, and PINK1, proteins involved in the regulation of 
mitophagy45,46. Results obtained did not show statistically significant changes for both Bnip3 mRNA and pro-
tein levels, although a small trend toward increased Bnip3 protein levels was visible in cachectic cancer patients 
(Fig. 3A,C). Similarly, we did not observe any significantly different change in Nix/Bnip3L (both m-RNA and 
protein levels), although a trend to increase was observed in non-cachectic patients with respect to both con-
trols and cachectic patients (mRNA) and in cancer patients (non-cachectic or cachectic) with respect to con-
trols (protein) (Fig. 3B,D). Parkin m-RNA was significantly increased in non-cachectic patients with respect to 
controls. In cachectic patients, Parkin m-RNA levels were not different with respect to controls, but significantly 
lower than in non-cachectic patients (Fig. 4A). Parkin protein levels were reduced with respect to controls in 
non-cachectic patients (Fig. 4C). In cachectic patients, Parkin protein levels were significantly higher than in 
non-cachectic patients, but were not different from controls (Fig. 4C). With regard to PINK1, m-RNA levels were 
significantly reduced in cachectic cancer patients with respect to controls and non-cachectic patients, whereas 
Figure 2. p62 expression in rectus abdominis muscle of cancer and control patients. (A) p62 mRNA levels 
were evaluated by real-time PCR (control, n = 11; non cachectic cancer patients, n = 17; cachectic cancer 
patients, n = 12); (B) p62 protein levels were evaluated by western blotting (control, n = 8; non cachectic cancer 
patients, n = 15; cachectic cancer patients, n = 10): representative western blots for p62 and GAPDH (loading 
control) are shown on the lower panel and densitometric quantifications of p62 protein levels normalized 
to GAPDH are shown on the upper panel. Data (mean ± SEM) are expressed as percentage of controls. 
Significance of the differences: * p < 0.05 vs controls.
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protein levels were not significantly modulated, although a trend toward increase in non-cachectic patients was 
observed (Fig. 4B,D).
Finally, since lysosomal dysfunction may contribute to defective autophagosome clearance and lead to their 
progressive accumulation, we assessed the expression of TFEB, a master upstream regulator of lysosomal biogen-
esis and autophagy, the activity of which is regulated by nutrient availability47. We found unchanged TFEB mRNA 
levels (Fig. 5A), and a trend toward higher TFEB nuclear protein levels in the skeletal muscle of cachectic cancer 
patients with respect to controls, although the differences did not reach statistical significance (Fig. 5B).
Discussion
The present study aimed at clarifying whether autophagy is modulated in the skeletal muscle of cancer patients. 
Some data supporting such hypothesis are already available in the literature. Indeed, other studies have shown 
increased protein levels for Beclin-1 and ATG5, another protein involved in the early stages of autophagosome 
formation48,49, in the rectus abdominis of weight losing upper gastrointestinal or pancreatic cancer patients33 and 
a LC3B-II/LC3B-I ratio higher than in controls has been observed in the vastus lateralis of esophageal cancer 
patients31. Moreover, up-regulation of LC3B-I and LC3B-II protein expression has been shown also in the vastus 
lateralis muscle of cachectic lung cancer patients32, further supporting the concept that autophagy is induced in 
the skeletal muscle of patients affected by different cancer types.
The results shown in the present study confirm and further extend those of previous reports, showing that 
beclin-1 and LC3 B-II protein levels are increased in the skeletal muscle of cancer patients. As for beclin-1, its 
over-expression is not paralleled by increased transcript levels, suggesting that it might simply reflect an impaired 
protein removal. Since we cannot evaluate autophagic flux in cancer patients, this alternative hypothesis cannot 
be discarded. However, a comparable mismatch between m-RNA and protein levels was observed in experimental 
conditions where the autophagic flux was dynamically assessed21. The observation that also p62 protein levels are 
increased in the muscle of cancer patients suggests that an accumulation of unprocessed autophagosomes might 
occur, possibly due to exhaustion of the lysosomal degradative capacity. Importantly, such autophagosome accu-
mulation could lead to dysfunction of cellular trafficking and marked abnormality of cytoskeleton organization in 
skeletal muscle fibers which may contribute to myofiber atrophy, loss of integrity and function5,17.
Figure 3. Bnip3 and Nix/Bnip3L expression in rectus abdominis muscle of cancer and control patients. 
 (A) Bnip3 and (B) Nix/Bnip3L mRNA levels were evaluated by real-time PCR (Bnip3: control, n = 8; non 
cachectic cancer patients, n = 16; cachectic cancer patients, n = 10; Nix/Bnip3L: control, n = 9; non cachectic 
cancer patients, n = 16; cachectic cancer patients, n = 11); (C) Bnip3 and (D) Nix/Bnip3L protein levels were 
evaluated by western blotting (Bnip3: control, n = 11; non cachectic cancer patients, n = 17; cachectic cancer 
patients, n = 10; Nix/Bnip3L: control, n = 3; non cachectic cancer patients, n = 5; cachectic cancer patients, 
n = 5): representative western blots for Bnip3, Nix/Bnip3L and GAPDH (loading control) are shown on the 
lower panel and densitometric quantifications of Bnip3 and Nix/Bnip3L protein levels normalized to GAPDH 
are shown on the upper panel. Data (mean ± SEM) are expressed as percentage of controls.
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Accumulation of p62, despite autophagy induction, has been observed also in the gastrocnemius of mice 
bearing the C26 or Lewis Lung carcinoma and in rats implanted with the Yoshida AH-130 hepatoma21. Moreover, 
in the muscle of C26-bearing mice on day 14 after tumor implantation, the increased p62 protein levels were asso-
ciated with reduced lysosomal cathepsin activities, suggesting that p62 accumulation may reflect disturbances in 
lysosomal function21. Conversely, in muscle biopsies of esophageal cancer patients increased LC3B-II/LC3B-I 
ratio and unchanged p62 protein level paralleled with increased cathepsin B and L activity31.
Mitophagy is a selective form of autophagy which plays an important role in removal of damaged mitochon-
dria, and regulation of mitochondria turnover and abundance, according to changes in metabolic requirements45. 
Impairment of mitophagy is deleterious to muscle homeostasis and leads to the accumulation of damaged and 
dysfunctional mitochondria15,46. Although several markers of mitophagy have been assessed, the results obtained 
in the present study do not clearly define if this process is activated above physiological levels in the patient 
population analyzed. We did not observe significant changes in the expression of Bnip3 and Nix/Bnip3L, two 
molecules implicated in recruiting the autophagosomes to damaged mitochondria4,46. Since both markers show 
a trend toward increase, it is possible that sample size is not large enough to provide significant results. Unlike 
in our study, increased Bnip3 mRNA levels have been found in muscle biopsies of lung32 and upper gastroin-
testinal50 cancer patients. In both studies32,50, however, Bnip3 increase was detected as mRNA expression only, 
and whether such increase is reflected at the protein level is not known. In addition to the Bnip3-Nix/Bnip3L 
system, the Parkin/PINK1 pathway is also involved in inducing mitophagy45,46. The increase in Parkin transcript 
observed in non- cachectic cancer patients, paralleled by a reduction in protein levels, would argue in favor of an 
increased mitophagic flux. Indeed, Parkin is anchored to the mitochondrial membrane and is degraded together 
with mitochondria51. Conversely, Parkin m-RNA and protein levels in cachectic patients showed different trends, 
suggesting possibly impaired mitophagy activation in the cachectic muscle with respect to cancer patients with-
out cachexia. The reduction of PINK1 expression in cachectic patients is consistent with findings in other forms 
of muscle depletion52 and further supports the view that mitophagy is impaired in human cancer cachexia. To our 
knowledge, this is the first description of a rather comprehensive panel of mitophagy markers in cancer patients. 
Figure 4. PINK1 and Parkin expression in rectus abdominis muscle of cancer and control patients.  
(A) PINK1 and (B) Parkin mRNA levels were evaluated by real-time PCR (PINK1: control, n = 9; non cachectic 
cancer patients, n = 16; cachectic cancer patients, n = 11; Parkin: control, n = 9; non cachectic cancer patients, 
n = 16; cachectic cancer patients, n = 11); (C) PINK1 and (D) Parkin protein levels were evaluated by western 
blotting (PINK1: control, n = 7; non cachectic cancer patients, n = 8; cachectic cancer patients, n = 9; Parkin: 
control, n = 7; non cachectic cancer patients, n = 8; cachectic cancer patients, n = 10): representative western 
blots for PINK1, Parkin and GAPDH (loading control) are shown on the lower panel and densitometric 
quantifications of PINK1 and Parkin protein levels normalized to GAPDH are shown on the upper panel. Data 
(mean ± SEM) are expressed as percentage of controls. Significance of the differences: * p < 0.05 vs controls; 
#p < 0.05 vs cancer no cachexia.
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We acknowledge, however, that patient sample size is limited and does not allow to draw definite conclusion on 
whether mitophagy represents a significant contributor to cancer-related muscle wasting.
The transcription factor TFEB is a master regulator of autophagosome and lysosome biogenesis47. In normal 
conditions, TFEB is phosphorylated by different kinases, including ERK2 and mTORC147,53, and is localized in 
the cytoplasm47,53,54. Upon starvation or lysosomal dysfunction, TFEB is dephosphorylated and rapidly trans-
locates to the nucleus where it becomes active and regulates the expression of target genes55. To the best of our 
knowledge, this is the first report of TFEB expression in the skeletal muscle of cancer patients. In the present 
study, however, not enough evidence was observed to claim a difference in TFEB m-RNA and nuclear protein 
level, a finding which is likely the consequence of the high inter-individual variability.
In this investigation, we provide new insights into the role of autophagy in cancer cachexia. However, the 
results obtained should be interpreted with caution since the study has several limitations. First, we evaluated a 
small sample of cancer patients who are not necessarily representative of the entire population. Second, we could 
just offer an approximate estimate of the autophagic flux, but not an actual evaluation of the autophagic rate, as 
it is possible in experimental models5,34. However, the dynamic assessment of muscle autophagic flux performed 
in C26-bearing mice, yelded a pattern of autophagic markers similar to the one reported here, supporting the 
conclusions of the present study. Third, it is not possible to ascertain whether the cross-sectional determination of 
muscle autophagy performed in our cancer patients is really representative of the entire time course of the disease. 
In fact, variations in autophagy could occur in the same patient because of changes in physical activity, nutrient 
availability or other variables which could potentially affect the clinical outcome. In this regard, unfortunately, 
we did not record nutritional intake neither energy expenditure for patients enrolled in the present study and it 
is not known to which extent these factors may have contributed to the results obtained. We screened patients 
for the presence of anorexia by using specific questionnaires, but, because the percentage of patients complain-
ing anorexia-related symptoms was quite similar among cachectic and non-cachectic cancer patients, it was not 
possible to draw any conclusions. Moreover, considering that most of the patients studied were aged > 65 years, 
Figure 5. TFEB expression in rectus abdominis muscle of cancer and control patients. (A) TFEB mRNA 
levels were evaluated by real-time PCR (control, n = 11; non cachectic cancer patients, n = 16; cachectic cancer 
patients, n = 12); (B) TFEB nuclear protein levels were evaluated by western blotting (control, n = 4; non 
cachectic cancer patients, n = 5; cachectic cancer patients, n = 3): representative western blots for TFEB and 
Lamin A (loading control) are shown on the lower panel and densitometric quantifications of TFEB protein 
levels normalized to Lamin A are shown on the upper panel. Data (mean ± SEM) are expressed as percentage of 
controls.
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we cannot exclude that the impairment in autophagosome removal was at least partially secondary to age-related 
sarcopenia4,21,22.
Finally, we have also to acknowledge that body composition in the present study was assessed by BIA a tech-
nique that, in spite of its several advantages (portability, ease of use, non invasivity, low cost) may have some 
limitations. Among these, it must be considered that BIA largely relies on the use of regression equations, which 
makes of BIA an indirect method to assess body composition. In addition, assessment may be less precise in 
patients with fluid imbalance, such as those with edema, liver cirrhosis and chronic kidney disease56,57. It must be 
noted, however, that in the present study, BIA measurements did not affect the final interpretation of our findings, 
since they were purely descriptive and they have not been used for interpretation of data at the molecular level.
In conclusion, the results obtained in the present study suggest that autophagy is induced in the skeletal mus-
cle of cachectic cancer patients although autophagosome clearance appears to be impaired, possibly because of 
exhaustion of the lysosomal degradative capacity. Mitophagy also seems impaired, although the results obtained 
are not conclusive.
The real challenge for future studies will be to better clarify if and to what extent is autophagy a determinant of 
cancer-related muscle wasting and whether targeting this pathway58,59 could represent a therapeutic strategy for 
cancer cachexia. These questions will remain unanswered, until the “yin and yang” of this obscure yet fascinating 
mechanism will be fully elucidated.
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